Anæmi * I studie 1100. 1090 (n = 28), hvor de fleste af de rapporterede tilfælde kommer fra, forekom granulocytopeni hos flere patienter i placebogruppen (3, 3%) end i nevirapingruppen (2, 5%).
* In study 1100.1090, from which the majority of related adverse events (n=28) were received, patients on placebo had a higher incidence of events of granulocytopenia (3.3%) than patients on nevirapine (2.5%).